Innovent Biologics, Inc. (IVBIY)

Market Cap	20.53B
Revenue (ttm)	1.59B
Net Income (ttm)	158.06M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	129.89
Forward PE	99.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113
Average Volume	282
Open	51.09
Previous Close	n/a
Day's Range	51.09 - 51.09
52-Week Range	19.15 - 52.00
Beta	0.21
RSI	67.22
Earnings Date	Nov 27, 2025

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,659
• Stock Exchange: OTCMKTS
• Ticker Symbol: IVBIY

Financial Performance

In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.

Financial numbers in CNY